ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NIH Plans Grants For Those Who Barely Miss Payline

April 19, 1991

NCI To Recompete Drug Discovery Groups In 2003 As Program Nears Its 20th Year

November 29, 2002

2015 Breakthrough Prize Winners Announced at Gala

November 14, 2014

Funding opportunities listed.

April 16, 2004

Kennedy Bills Would Raise Salaries, Restore Construction, Expand Biomedical Research Support

July 14, 1989

In Brief: Increased Output Can Hold Down High Let Cost, Kligerman says; No More Groups On The Block

March 18, 1977